Bio

Dr. Adrian Hugenmatter joined ChEM-H in 2021 and is leading the Protein Therapeutics Knowledge Center. In this role he is also responsible for IMAs Protein Therapeutic module. Dr. Hugenmatter received his PhD in the laboratory of Prof. Donald Hilvert at the Swiss Federal Institute of Zurich (ETH Zurich, Switzerland), where he gained initial experience in enzymology, antibody engineering and directed evolution. Fascinated by protein engineering, he joined the laboratory of Prof. Dan Tawfik at the Weizmann Institute of Science (Israel), where he studied molecular evolution and its application in protein design. Afterwards, Dr. Hugenmatter worked as a research scientist and team leader at Roche for more than a decade. During that time, he was involved in the development and optimization several antibody lead candidates for therapeutic applications in Neuroscience and Oncology.

Academic Appointments

Honors & Awards

  • Roche Innovator Award, Roche (2014)
  • Fellowship, Swiss Society of Friends of the Weizmann Institute (2007)

Patents

  • Lorenzo Deho, Christian Gassner, Sylvia Herter, Thomas Hofer, Ralf Hosse, Adrian Hugenmatter, Christian Klein, Florian Limani, Ekkehard Moessner, Melanie Obba, Bianca Scherer, Pablo Umaña. "Switzerland Patent WO2022117692A3 pH-dependent Mutant Interleukin-2 Polypeptides", Hoffmann-La Roche Inc., Dec 2, 2021
  • Petra Rueger, Georg Tiefenthaler, Ekkehard Moessner, Jens Niewoehner, Adrian Hugenmatter, Cuiying shao, Francesca Ros, Gang Xu. "United States Patent US2017051071A1 Monovalent Blood Brain Barrier Shuttle Modules", Hoffmann-La Roche Inc., Jul 6, 2016
  • Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady. "United States Patent US2016376352A1 Humanzed Anti-Tau(pS422) Antibodies and Methods of Use", Hoffmann-La Roche Inc., Jun 22, 2016
  • Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Peter Bruenker, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Adrian Hugenmatter, Christiane Jaeger, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana. "United States Patent US2017327579A1 Bispecific Antibodies against CD3epsilon and BCMA", ENGMAB AG, Nov 18, 2015
  • Bernd Bohrmann, Per-Ola Freskgard, Adrian Hugenmatter, Erhard Kopetzki, Ekkehard Moessner, Jens Niewoehner, Hadassah Sumum Sade, Pablo Umana. "United States Patent US2012282176A1 Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier", Roche Glycart AG, Nov 8, 2012

Contact

  • Academic
    adrianhu@stanford.edu
    University - Academic staff Department: ChEM-H Operations Position: Director of Protein Engineering
    • 3160 PORTER DR
    • Suite 120
    • PALO ALTO,  California  94304 

Additional Info

  • Mail Code: 5082